BACKGROUND The optimal systolic blood pressure (SBP) treatment goal is in question, with SPRINT (Systolic Blood
(Heart Outcomes Prevention Evaluation) trial (7) .
Achieving intensive SBP reductions will inevitably also lower DBP. For example, in a secondary analysis of elderly SPRINT participants, the authors reported that DBP in the intensive-therapy arm fell from a mean of 71.5 mm Hg at baseline to 62 mm Hg during active treatment (9) . This is of potential concern due to the known J-curve for DBP and coronary artery disease (CAD) events (10) (11) (12) . Particularly among persons with obstructive CAD or left ventricular hypertrophy (LVH), a drop in DBP has been shown to reduce coronary perfusion pressure (coronary blood flow occurs primarily in diastole), which can result in ischemia and myocardial damage (13) .
High-sensitivity cardiac troponin assays can detect asymptomatic myocardial damage and have been strongly predictive of fatal and nonfatal coronary heart disease (CHD) events in numerous observational studies, including among primary prevention populations (14) (15) (16) (17) . As such, high-sensitivity cardiac troponin-T (hs-cTnT) may be of value in understanding whether a lower achieved BP, and particularly a low DBP level, is associated with myocardial damage.
Therefore, the aim of this analysis from the ARIC (Atherosclerosis Risk In Communities) cohort study was to determine whether low DBP was associated with either cross-sectional (measured with hs-cTnT at baseline) or progressive (measured with trajectories of temporal hs-cTnT change over follow-up) subclinical myocardial damage. We also evaluated whether low DBP increases the risk for future adverse outcomes, including CHD, stroke, and all-cause death, in the overall study sample as well as after stratification by baseline SBP and baseline hs-cTnT (given that levels $14 ng/l are associated with structural heart disease, such as LVH, and subclinical macro/ microvascular coronary disease).
METHODS
The ARIC study is a prospective observational cohort of 15,792 adults sampled from 4 U.S. communities (Forsyth Country, North Carolina; Jackson, Mississippi; suburban Minneapolis, Minnesota; and Washington County, Maryland). Study design details have been published (18) . Institutional review boards at each site approved the study, and written informed consent was obtained from all participants. Of the 14,348 persons who attended ARIC visit 2 (1990 to 1992), we excluded those with known cardiovascular disease or HF at or prior to visit 2 (n ¼ 1,651) and those missing other variables of interest (n ¼ 1,132). Thus, 11,565 persons were included in our main analytic sample (Online Table 1 ). For supplemental analyses we generated a secondary subsample of 1,403 visit 2 participants who met SPRINT enrollment criteria (8) (Online Appendix).
MEASUREMENT OF EXPOSURE VARIABLES. Measurement of hs-cTnT occurred at 3 time points over a span of 21 years: visit 2 (1990 to 1992), visit 4 (1996 to 1998), and visit 5 (2011 to 2013). The measurement range of the assay is 3 to 100,000 ng/l. Values $14 ng/l represent the 90th percentile in the ARIC sample and the 99th percentile value for a "healthy" reference group ages 20 to 70 years (19) . Additional details on hs-cTnT measurements at each visit are available in the Online Appendix.
Demographic and cardiovascular risk factors were assessed at visit 2, with measurements obtained using standardized protocols (18) . Participants selfreported race, alcohol use, and smoking status.
Body mass index (BMI) was calculated from measured weight and height. After 5 min of seated rest, we recorded BP as the mean of the last 2 of 3 measurements collected over 5-min intervals using a random zero sphygmomanometer. Hypertension was defined as SBP $140 mm Hg, DBP $90 mm Hg, or the use of antihypertensive medications. Antihypertensive drug use was assessed using a medication inventory.
Diagnosed diabetes was defined as a self-reported physician diagnosis of diabetes or current use of diabetic medications. Total cholesterol, high-density lipoprotein cholesterol, and triglyceride measurements were obtained after a 12-h fast. Low-density lipoprotein cholesterol was calculated using the Friedewald equation.
FOLLOW-UP FOR CLINICAL OUTCOMES OF INTEREST.
Clinical endpoints included CHD, stroke, and 
Diastolic BP and Cardiac Outcomes All models were tested for interaction by age, sex, and race. The level of significance was defined as p < 0.05 (2-sided).
RESULTS
Per characteristics of the sample by baseline DBP, individuals with lower DBP tended to be older, female, white, have lower BMI, and have healthier lipid profiles ( however, these findings were not statistically significant (Online Table 3 ).
Low DBP at baseline also was independently Values are n (%), mean AE SD, or %. *Categories of diastolic blood pressure (DBP) at baseline (ARIC visit 2, [1990] [1991] [1992] .
BMI ¼ body mass index; ECG ¼ electrocardiograph; eGFR ¼ estimated glomerular filtration rate; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; SBP ¼ systolic blood pressure.
Diastolic BP and Cardiac Outcomes -, 2016:---However, DBP at visit 2 was not associated with higher annual hs-cTNT change in the follow-up period occurring after visit 4 (i.e., from 1996 to 1998 to visit 5 in 2011 to 2013) ( Table 2) . Table 3) . When evaluating the subcomponents of CHD outcome, this association appeared stronger for fatal CHD and myocardial infarction, relative to revascularization (Online Table 4 ). As expected, there was no association between DBP and stroke after accounting for SBP and clinical confounders ( Table 3) .
The results of our supplemental analysis for incident HF were similar to those for CHD, with a trend for increased risk at low DBP (Online Table 5 ). Additionally, we found similar associations between low DBP and CHD events in the SPRINT-eligible subsample (Online Table 6 ). Furthermore, DBP <60 mm Hg was consistently associated with excess risk for events in our sensitivity analysis evaluating DBP as a timevarying exposure and with adjustment for SBP, antihypertensive medication use, and renal function as time-varying confounders (Online Table 7 ).
When our primary sample was stratified by baseline antihypertensive treatment status, the association between DBP categories and CHD events was qualitatively similar as in the sample overall (Online Table 8 ). However, when the sample was stratified by baseline hs-cTnT (<14 or $14 ng/l), the risk for Table 8 ).
After stratifying the study sample by SBP categories, both myocardial damage and clinical event outcomes varied according to baseline DBP levels ( Table 4 ). The association of low DBP (specifically DBP <60 mm Hg) with both prevalent myocardial damage and incident CHD appeared to be primarily driven by excess risk among those with an SBP $120 mm Hg (in other words, pulse pressure >60 mm Hg).
These results were consistent in a number of sensitivity analyses, demonstrating that: 1) low DBP, modeled continuously, is a risk factor for elevated hscTnT and incident CHD (particularly after adjusting for SBP) (Online Figure 1) ; 2) despite the adverse associations with low DBP, high SBP is also a risk factor for elevated hs-cTnT and incident CHD (Online Significant values are indicated in bold. *According to DBP level, after stratification by SBP. †Adjusted for same variables as in Table 2 , except for SBP. ‡Logistic model for cross-sectional association between DBP and baseline elevated hs-cTnT. §Cox model for prospective association between DBP and incident events.
Abbreviations as in Tables 1 to 3 . ischemia by lowering DBP. This is a concern on the basis of strong physiological rationale and a wealth of prior observational data. Indeed, there was a trend toward harm with intensive BP treatment among participants enrolled in the HOPE-3 (Heart Outcomes Prevention Evaluation-3) study who had a baseline SBP <131.5 mm Hg (7). We extended these findings by demonstrating that, at any given SBP: 1) low DBP was cross-sectionally associated with prevalent myocardial damage; 2) low DBP was prospectively associated We also found weaker associations with mortality at the lowest DBP levels. Given the results for CHD, the association between low DBP and incident HF that we demonstrated in our sensitivity analysis may represent ischemic heart failure events. In contrast, there were no associations found for stroke, our These results suggest that discordance between SBP and DBP (i.e., elevated pulse pressure) might be an important factor linking low DBP to myocardial outcomes (29) . Indeed, because systolic pressure is the main determinant of cardiac afterload and, thus, a primary driver of myocardial energy requirements (30), it is not surprising that our results appear to demonstrate that adverse myocardial outcomes seem most likely when both DBP is low (when myocardial energy supply is reduced due to lower coronary perfusion pressure) and SBP is $120 mm Hg (when myocardial energy demand is higher).
STUDY LIMITATIONS. This was an observational study, and our inferences might not reflect direct causal effects. For example, we cannot know for sure whether the association between low DBP and outcomes in our analysis was due to low DBP from drug treatment, from arterial stiffness, or from a combi- jmcevoy1@jhmi.edu.
R E F E R E N C E S

